Prescribing Information for the Patient
Galafold 123 mg Hard Capsules
Migalastat
Read this entire prescribing information carefully before starting to take this medicine, as it contains important information for you.
Galafold contains the active ingredient migalastat.
This medication is used for the long-term treatment of Fabry disease in adults and adolescents 12 years of age and older who carry certain genetic mutations (changes in the genetic material).
Fabry disease is caused by a deficiency of an enzyme called alpha-galactosidase A(α-Gal A). Depending on the type of mutation (change in the genetic material) of the gene that produces α-Gal A, the enzyme may not function correctly or be entirely absent. This enzyme deficiency causes abnormal accumulations of a fatty substance known as globotriaosylceramide (GL-3) in kidneys, heart, and other organs, leading to the symptoms of Fabry disease.
This medication works by stabilizing the enzyme that the body naturally produces, allowing it to function better to reduce the amount of GL-3 accumulated in cells and tissues.
Do not take Galafold:
Warnings and precautions
The 123 mg migalastat capsules are not indicated for children(≥12years) weighing less than
45 kg of body weight.
Inform your doctor before taking Galafold if you are using enzyme replacement therapy.
You should not take Galafold if you are also using enzyme replacement therapy.
While taking Galafold, your doctor should assess your condition and whether your medication is working every 6 months. If your condition worsens, your doctor should perform additional tests or discontinue Galafold treatment.
Consult your doctor before taking Galafold if your renal function is severely impaired, as Galafold is not recommended for patients with severe renal insufficiency (with a GFR below 30ml/min/1.73m2).
Children
Children <12>
This medication has not been studied in children under 12 years of age. Consequently, the safety and efficacy have not been established in this age range.
Other medications and Galafold
Inform your doctor, pharmacist, or nurse if you are taking, have taken recently, or may take any other medication.This includes over-the-counter medications, such as supplements or herbal medications.
Inform your doctor especially if you take medications or supplements containing caffeine, as these medications may affect Galafold activity if taken during fasting.
Be aware of the medications you take. Keep a list of them and show it to your doctor and pharmacist each time you obtain a new medication.
Pregnancy, breastfeeding, and fertility
Pregnancy
There are very limited data regarding the use of this medication in pregnant women. Galafold is not recommended during pregnancy. If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor before using this medication.
Women who may become pregnant should use an effective contraceptive method while using Galafold.
Breastfeeding
Do not take this medication if you are breastfeeding your child until you have consulted with your doctor, pharmacist, or nurse. It is not known whether this medication is excreted in breast milk. Your doctor will decide whether you should discontinue breastfeeding or temporarily suspend treatment, considering the benefits of breastfeeding for the baby and the benefits of Galafold for the mother.
Male fertility
It is not known whether this medication affects male fertility. Galafold has not been studied in human fertility.
Female fertility
It is not known whether this medication affects female fertility.
If you plan to become pregnant, consult your doctor, pharmacist, or nurse.
Driving and operating machinery
This medication is not expected to affect your ability to drive and operate machinery.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor, pharmacist, or nurse.
The recommended dose is one capsule every two days at the same time of day. Do not take Galafold for two consecutive days.
Do not ingest any food or caffeine for at least 2 hours before and 2 hours after taking the medication. This minimum 4-hour fasting period around the time of medication intake is necessary to allow the medication to be fully absorbed.
During the 4-hour fasting period, you can consume water (natural, flavored, sweetened), fruit juice without pulp, and caffeine-free carbonated beverages.
Swallow the capsules whole. Do not break, crush, or chew the capsules.
Figure A | Step 1: Remove the adhesive strip that keeps the flap closed. Lift the flap to open the Galafold carton (see Figure A). |
Figure B: Open carton | Step 2: Press the purple button with your thumb on the left side of the carton without releasing it (see Figure B) and proceed to step 3. |
Figure C | Step 3: Now GRAB the button by the right side, where it says “PULL FROM HERE”, and remove the folded blister (see Figure C). |
Figure D: Frontal face of the blister | Step 4: Unfold the blister (see Figure D). |
How to take Galafold capsules: One Galafold blister = 14 hard capsules = 28 days of Galafold treatment and 14 white circles. The white circles serve to remind you to take Galafold every two days. The arrow indicates the patient to start the next 2 weeks of treatment. Figure E: Frontal face of the blister | |
Figure F: Frontal face of the blister | Step 5: On the first day you start with this medication, mark the date on the new blister. (see Figure F). |
Figure G: Back face of the blister | Step 6: TURN THE BLISTER OVER to see the back face. LOCATE the capsule to be extracted. DOUBLES the blister as indicated here (see Figure G). Nota: When DOUBLING the blister, the perforated oval protrudes. |
| Step 7: REMOVE the perforated oval (see Figure H). Nota: When removing the oval, it is possible that the white support sheet remains. This is correct. |
Figure I: Frontal face of the blister | Step 8: TURN THE BLISTER OVER to see the frontal face. PUSH the capsule to remove it (see Figure I). |
Figure J: Frontal face of the blister | Step 9: The next day, move to the white circle from the top row marked as Day 2. Press the white circle to perforate it (see Figure J). Nota: Perforating this white circle will help you remember which days not to take the medication. Take 1 Galafold capsule every two days. Close and store the box after each use. |
After Day 2, move to Day 3 of the blister. Alternate the days you take the capsule and perforate the white circles, until Day 28, inclusive. Figure K: Frontal face of the unfolded blister |
If you take more Galafold than you should
If you take more capsules than you should, stop taking the medication and consult your doctor. You may experience headaches and dizziness.
If you forget to take Galafold
If you forget to take the capsule at the usual time and remember later, you can take the capsule only if it is within the 12-hour interval following the usual time to take the dose. If more than 12 hours have passed, you should resume Galafold on the corresponding day and at the usual time, according to the dosing schedule of alternate days. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Galafold
You should not interrupt treatment without first speaking with your doctor.
If you have any other doubts about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medications, this medication may produce adverse effects, although not all people may experience them.
Very Common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
|
|
|
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through thenational notification system included in theAppendix V. By reporting adverse effects, you can contribute to providing more information about the safetyof this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and the blister pack after CAD. The expiration date is the last day of the month indicated.
This medication does not require any special storage temperature. Store in the original packaging to protect it from moisture.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Galafold Composition
Capsule content: pregelatinized maize starch and magnesium stearate
Capsule coating: gelatin, titanium dioxide (E171) and indigo carmine (E132)
Printing ink: shellac, iron oxide black and potassium hydroxide
Appearance of Galafold and packaging contents
Hard blue and white opaque capsules marked with "A1001" in black ink, hard capsule size 2 (6.4 x 18.0 mm) containing a white to light brown powder.
Galafold is available in a blister pack of 14 capsules.
Marketing Authorization Holder
Amicus Therapeutics Europe Limited
Block 1, Blanchardstown Corporate Park
Ballycoolin Road
Blanchardstown, Dublin
D15 AKK1
Ireland
Tel: +353 (0) 1 588 0836
Fax: +353 (0) 1 588 6851
e-mail:[email protected]
Manufacturer
Almac Pharma Services (Ireland) Limited
Finnabair Industrial Estate
Dundalk, Co. Louth
A91 P9KD
Ireland
You can request more information about this medicine by contacting the local representative of the marketing authorization holder (if you cannot contact your Amicus representative by phone, please contact us via the following email address):
Belgium Amicus Therapeutics Europe Limited Tel: (+32) 0800 89172 e-mail: [email protected] | Lithuania Amicus Therapeutics Europe Limited Tel.: (+370) 8800 33167 e-mail: [email protected] |
Bulgaria Amicus Therapeutics Europe Limited Phone: (+359) 00800 111 3214 Email:[email protected] | Luxembourg Amicus Therapeutics Europe Limited Tel/Tel: (+352) 800 27003 e-mail: [email protected] |
Czech Republic Amicus Therapeutics Europe Limited Tel.: (+420) 800 142 207 e-mail:[email protected] | Hungary Amicus Therapeutics Europe Limited Tel.: (+36) 06 800 21202 e-mail: [email protected]om |
Denmark Amicus Therapeutics Europe Limited Tlf.: (+45) 80 253 262 e-mail: [email protected] | Malta Amicus Therapeutics Europe Limited Tel: (+356) 800 62674 e-mail: [email protected] |
Germany Amicus Therapeutics GmbH Tel.: (+ 49) 0800 000 2038 E-Mail: [email protected] | Netherlands Amicus Therapeutics BV Tel: (+ 31) 0800 022 8399 e-mail: [email protected] |
Estonia Amicus Therapeutics Europe Limited Tel: (+372) 800 0111 911 e-post: [email protected] | Norway Amicus Therapeutics Europe Limited Tlf: (+47) 800 13837 e-post: [email protected] |
Greece Amicus Therapeutics Europe Limited Phone: (+30) 00800 126 169 e-mail:[email protected] | Austria Amicus Therapeutics Europe Limited Tel: (+43) 0800 909 639 E-Mail: [email protected] |
Spain Amicus Therapeutics S.L.U. Tel: (+34) 900 941 616 e-mail: [email protected] | Poland Amicus Therapeutics Europe Limited Tel.: (+48) 0080 012 15475 e-mail: [email protected] |
France Amicus Therapeutics SAS Tél: (+33) 0 800 906 788 e-mail: [email protected] | Portugal Amicus Therapeutics Europe Limited Tel: (+351) 800 812 531 e-mail: [email protected] |
Croatia Amicus Therapeutics Europe Limited Tel: (+385) 0800 222 452 e-pošta: [email protected] | Romania Amicus Therapeutics Europe Limited Tel.: (+40) 0808 034 288 e-mail: [email protected] |
Ireland Amicus Therapeutics Europe Limited Tel: (+354) 1800 936 230 e-mail: [email protected] | Slovenia Amicus Therapeutics Europe Limited Tel.: (+386) 0800 81794 e-pošta: [email protected] |
Iceland Amicus Therapeutics Europe Limited Phone: (+354) 800 7634 Email: [email protected] | Slovakia Amicus Therapeutics Europe Limited Tel.: (+421) 0800 002 437 e-mail: [email protected] |
Italy Amicus Therapeutics S.r.l. Tel: (+39) 800795 572 e-mail: [email protected] | Finland Amicus Therapeutics Europe Limited Tel: (+358) 0800 917 780 e-mail: [email protected] |
Cyprus Amicus Therapeutics Europe Limited Phone: (+357)800 97595 e-mail:[email protected] | Sweden Amicus Therapeutics Europe Limited Tfn: (+46) 020 795 493 e-post: [email protected] |
Lithuania Amicus Therapeutics Europe Limited Tel.: (+371) 800 05391 e-pasts: [email protected] | United Kingdom (Northern Ireland) Amicus Therapeutics, UK Limited Tel: (+44) 08 0823 46864 e-mail: [email protected] |
Last update of this leaflet
For detailed information about this medicine, please visit the website of the European Medicines Agency:http://www.ema.europa.eu. There are also links to other websites about rare diseases and orphan medicines.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.